drugset / Trial / NCT04971551
A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
NaSingle-groupOpen-labelTreatment
Summary
This is an single-arm, Phase II multi-center study. The purpose of this study is to assess the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease.
Timeline
- Start
- 2024-12
- Primary completion
- 2025-06
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 75 mg | Oral |
| Subject | Jaktinib | Unknown | 100 mg | Oral |